Protein Degradation & Targeting Undruggables Europe 2022

Facilitate successful clinical translation of PROTACs and Molecular Glues by expanding target classes and the ligase landscape through rational discovery & design paradigms beyond oncology

VIEW THE 2022 AGENDA
Congress Centre, Basel, Switzerland
11-12 October, 2022

“Very interesting topic with cutting edge science presented by both pharma and academia.”

Rossella Guidetti, Lilly

“A lot of data on PROTAC research has been disclosed at this event. And also, many leaders in PROTACs shared their experience and concerns about their development. Many start-up companies also delivered their progress. We are able to discuss future directions as well as difficulties with experts from both industry and the academic area and learned a lot.”

Yuqing Huang Suzhou, Kintor Pharmaceuticals

Why Attend

The field of protein degradation has accelerated, and substantial interest is owed to its promise to therapeutically degrade proteins proving intractable to classical small molecule inhibition.

As the field patiently waits for clinical trial readouts, some say we are entering the next era, beyond current targets and disease indications. Ongoing research efforts in academia and industry prepare us for the next wave of challenges that need to be overcome:

  • Building up the foundational knowledge in the molecular glue space through novel rational glue discovery and design approaches and innovative structural tools to model ternary interactions
  • Novel strategies towards defining and clinically demonstrating the most optimal target classes and boosting the current E3 ligase repertoire beyond CRBN- and VHL-based mechanisms
  • Innovative approaches towards improved drug-like properties showcasing optimized oral bioavailability and DMPK/ADMET profiles to bring us a step closer to optimized clinical translation
  • Case studies that investigate TPD opportunities outside the realm of oncology while addressing potentially disguised hurdles therein and acquired resistance mechanisms

The fourth annual Protein Degradation & Targeting Undruggables European Congress provides a unique opportunity to assess recent developments in the implementation of novel technologies to further discovery, design and subsequent development of TPD-based therapies while engaging with the most senior experts in industry and academia in the region.

Join us in contributing to this ongoing effort to push away from the foundational era exploring the full potential of targeted protein degradation
as a novel therapeutic option across diverse indications.

Previous Attendees Include

Audience Breakdown

2022 Speakers

 

Ingrid Wertz

Executive Director, Protein Homeostasis Center of Excellence
BMS

Ingrid Wertz

Executive Director, Protein Homeostasis Center of Excellence
BMS

Ingrid Wertz

Executive Director, Protein Homeostasis Center of Excellence
BMS
 

Danette Daniels, Ph.D.

VP, Protein Degrader Platform
Foghorn Therapeutics

Danette received her B.A. from Columbia University, Ph.D. in Biophysics from Yale University, and completed a postdoctoral fellowship at Stanford University School of Medicine studying Wnt signaling pathway.  She has been at Promega Corporation for 15 years and is currently an R&D Group Leader of Functional Proteomics.  She leads a team developing technologies and performing research to understand dynamic intracellular interactions within the focus areas of epigenetics, targeted protein degradation, and drug discovery.

Danette Daniels, Ph.D.

VP, Protein Degrader Platform
Foghorn Therapeutics

Danette Daniels, Ph.D.

VP, Protein Degrader Platform
Foghorn Therapeutics

Danette received her B.A. from Columbia University, Ph.D. in Biophysics from Yale University, and completed a postdoctoral fellowship at Stanford University School of Medicine studying Wnt signaling pathway.  She has been at Promega Corporation for 15 years and is currently an R&D Group Leader of Functional Proteomics.  She leads a team developing technologies and performing research to understand dynamic intracellular interactions within the focus areas of epigenetics, targeted protein degradation, and drug discovery.

 

Adam Gilbert

Executive Director, Head of Design and Synthesis Sciences
Pfizer

My group supports several important medchem platforms for Pfizer: protein degradation, DNA-encoded library chemistry, large and small-scale compound purification and phenotypic screening deconvolution.  Scientists in my group specialize in design and synthetic medicinal chemistry, computational chemistry, purification science as well as molecular property analysis.

Adam Gilbert

Executive Director, Head of Design and Synthesis Sciences
Pfizer

Adam Gilbert

Executive Director, Head of Design and Synthesis Sciences
Pfizer

My group supports several important medchem platforms for Pfizer: protein degradation, DNA-encoded library chemistry, large and small-scale compound purification and phenotypic screening deconvolution.  Scientists in my group specialize in design and synthetic medicinal chemistry, computational chemistry, purification science as well as molecular property analysis.

 

Karen Miller

Senior Scientist
BioTheryX

Karen Miller

Senior Scientist
BioTheryX

Karen Miller

Senior Scientist
BioTheryX
 

Greg Hollingworth

Director, New Modalities & TPD Global Initiatives Co-Lead
Novartis

Greg Hollingworth

Director, New Modalities & TPD Global Initiatives Co-Lead
Novartis

Greg Hollingworth

Director, New Modalities & TPD Global Initiatives Co-Lead
Novartis
 

Simon Bailey

Executive Vice President, Head of Drug Discovery
Plexium

Simon Bailey

Executive Vice President, Head of Drug Discovery
Plexium

Simon Bailey

Executive Vice President, Head of Drug Discovery
Plexium
 

Manfred Koegl

Director of Oncology Research
Boehringer Ingelheim

I am a director in Oncology Research at Boehringer Ingelheim in Vienna, working on the discovery and implementation of new therapeutic concepts in cancer. The main focus of my team are novel approaches for cancer cell targeting by small molecule drugs.

Manfred Koegl

Director of Oncology Research
Boehringer Ingelheim

Manfred Koegl

Director of Oncology Research
Boehringer Ingelheim

I am a director in Oncology Research at Boehringer Ingelheim in Vienna, working on the discovery and implementation of new therapeutic concepts in cancer. The main focus of my team are novel approaches for cancer cell targeting by small molecule drugs.

 

Stefan Knapp

Professor, Principal Investigator
Goethe University

Stefan Knapp

Professor, Principal Investigator
Goethe University

Stefan Knapp

Professor, Principal Investigator
Goethe University
 

Celia Bisbach

Research Scientist
Promega

Celia Bisbach

Research Scientist
Promega

Celia Bisbach

Research Scientist
Promega
 

Sara Pannilunghi

University of Geneva

Sara Pannilunghi

University of Geneva

Sara Pannilunghi

University of Geneva
 

Agnieszka Konopacka

Principal Scientist
GSK

Agnieszka Konopacka

Principal Scientist
GSK

Agnieszka Konopacka

Principal Scientist
GSK
 

Satpal Virdee

Professor, Chemical Biology
MRC Protein Phosphorylation and Ubiquitylation Unit, University of Dundee

Satpal Virdee

Professor, Chemical Biology
MRC Protein Phosphorylation and Ubiquitylation Unit, University of Dundee

Satpal Virdee

Professor, Chemical Biology
MRC Protein Phosphorylation and Ubiquitylation Unit, University of Dundee
 

Mikolaj Slabicki

Group Leader, Senior Scientist
DFCI / Broad Institute

Mikolaj Slabicki

Group Leader, Senior Scientist
DFCI / Broad Institute

Mikolaj Slabicki

Group Leader, Senior Scientist
DFCI / Broad Institute
 

Tom Shepherd

Captor Therapeutics

Tom Shepherd

Captor Therapeutics

Tom Shepherd

Captor Therapeutics
 

Elmar Wolf

Professor
University of Wurzbug

Elmar Wolf

Professor
University of Wurzbug

Elmar Wolf

Professor
University of Wurzbug
 

Zuzanna Kozicka

PhD Candidate
Friedrich Miescher Institute for Biomedical Research

I am a PhD student in the laboratory of Nicolas Thomä at the Friedrich Miescher Institute in Basel, Switzerland. I have an avid interest in molecular glue degraders and, more generally, in understanding how changes in protein interactomes can be brought about by the binding of small molecules. Prior to joining the Thomä lab, I completed my studies at the University of Edinburgh and I undertook various research projects, including one in the laboratory of Alessio Ciulli at the University of Dundee that focussed on PROTAC ‘linkerology’.

Zuzanna Kozicka

PhD Candidate
Friedrich Miescher Institute for Biomedical Research

Zuzanna Kozicka

PhD Candidate
Friedrich Miescher Institute for Biomedical Research

I am a PhD student in the laboratory of Nicolas Thomä at the Friedrich Miescher Institute in Basel, Switzerland. I have an avid interest in molecular glue degraders and, more generally, in understanding how changes in protein interactomes can be brought about by the binding of small molecules. Prior to joining the Thomä lab, I completed my studies at the University of Edinburgh and I undertook various research projects, including one in the laboratory of Alessio Ciulli at the University of Dundee that focussed on PROTAC ‘linkerology’.

 

Lurong Pan

CEO
Ainnocence

Lurong Pan

CEO
Ainnocence

Lurong Pan

CEO
Ainnocence
 

Allan Jordan

Director, Oncology Drug Discovery
Sygnature Discovery

Allan Jordan

Director, Oncology Drug Discovery
Sygnature Discovery

Allan Jordan

Director, Oncology Drug Discovery
Sygnature Discovery
 

Martin Steger

Scientist MS-Based Proteomics
Max Planck Institute of Biochemistry

Martin Steger

Scientist MS-Based Proteomics
Max Planck Institute of Biochemistry

Martin Steger

Scientist MS-Based Proteomics
Max Planck Institute of Biochemistry
 

Matthieu Schapira

Professor, Principal Investigator
University of Toronto

Matthieu Schapira

Professor, Principal Investigator
University of Toronto

Matthieu Schapira

Professor, Principal Investigator
University of Toronto
 

Stephanie Voss

Director, Biochemistry & Biophysics
Oerth Bio

Stephanie Voss

Director, Biochemistry & Biophysics
Oerth Bio

Stephanie Voss

Director, Biochemistry & Biophysics
Oerth Bio
 

Hyunsun Jo

CEO
Pin Therapeutics

Hyunsun Jo

CEO
Pin Therapeutics

Hyunsun Jo

CEO
Pin Therapeutics
 

Ivan Dikic

Professor, Director
Goethe University

Ivan Dikic

Professor, Director
Goethe University

Ivan Dikic

Professor, Director
Goethe University
 

Felix Hausch

Professor
Technical University Darmstadt

Felix Hausch

Professor
Technical University Darmstadt

Felix Hausch

Professor
Technical University Darmstadt
 

Giulia Caron

Professor, Medicinal Chemistry
University of Turin

Giulia Caron

Professor, Medicinal Chemistry
University of Turin

Giulia Caron

Professor, Medicinal Chemistry
University of Turin
 

Yusuke Tominari

Chief Executive Officer/Chief Scientific Officer
FIMECS, Inc.

Yusuke Tominari is a CEO and CEO, and manages the entire projects and strategy of FIMECS, Inc. He curved out from Takeda pharmaceutical company limited with his colleagues and launched FIMECS in 2018. He started his career of medicinal chemist at Takeda in 2006 after getting a PhD at the University of Tokyo in Japan. Through his 12 years of pharmaceutical experience, he has been mainly working on immunology and oncology areas.

Yusuke Tominari

Chief Executive Officer/Chief Scientific Officer
FIMECS, Inc.

Yusuke Tominari

Chief Executive Officer/Chief Scientific Officer
FIMECS, Inc.

Yusuke Tominari is a CEO and CEO, and manages the entire projects and strategy of FIMECS, Inc. He curved out from Takeda pharmaceutical company limited with his colleagues and launched FIMECS in 2018. He started his career of medicinal chemist at Takeda in 2006 after getting a PhD at the University of Tokyo in Japan. Through his 12 years of pharmaceutical experience, he has been mainly working on immunology and oncology areas.

FIMECS, Inc. is a drug discovery biotech developing a new class of drugs based on targeted protein degradation therapeutics for currently ‘undruggable’ targets in immune-oncology and oncology areas.

Utilizing our drug discovery platform, RaPPIDSTM to internal and collaborative programs, we rapidly discover therapeutic candidates to induce the degradation of disease-relevant targeted proteins.

Most important mission is the providing life-saving medicines to patients all over the world.

 

Zachary Carpenter

Founder, CEO
VantAI

Zachary Carpenter

Founder, CEO
VantAI

Zachary Carpenter

Founder, CEO
VantAI
 

Elisabeth Hennes

Senior Scientist
Almirall

Elisabeth Hennes

Senior Scientist
Almirall

Elisabeth Hennes

Senior Scientist
Almirall
 

Carlotta Cecchini

PhD Candidate, Pharmaceutical Biochemistry/Chemistry
University of Geneva

Carlotta Cecchini

PhD Candidate, Pharmaceutical Biochemistry/Chemistry
University of Geneva

Carlotta Cecchini

PhD Candidate, Pharmaceutical Biochemistry/Chemistry
University of Geneva
 

Ted Suh

VP, Chemistry
Orionis Biosciences

Ted Suh

VP, Chemistry
Orionis Biosciences

Ted Suh

VP, Chemistry
Orionis Biosciences
 

Katherine Donovan

Lead Scientist, Fischer Lab
DFCI

Katherine Donovan

Lead Scientist, Fischer Lab
DFCI

Katherine Donovan

Lead Scientist, Fischer Lab
DFCI
 

Jan Kröenke

Professor
Charité- Universitätsmedizin Berlin

Jan Kröenke

Professor
Charité- Universitätsmedizin Berlin

Jan Kröenke

Professor
Charité- Universitätsmedizin Berlin
 

Andreas Langer

Principal Scientist
NanoTemper Technologies

Andreas Langer

Principal Scientist
NanoTemper Technologies

Andreas Langer

Principal Scientist
NanoTemper Technologies
 

Jutta Blank

Director, Chemical Biology
Novartis

Jutta Blank

Director, Chemical Biology
Novartis

Jutta Blank

Director, Chemical Biology
Novartis
 

Markus Müllner

CSO
Celeris Therapeutics

Markus Müllner

CSO
Celeris Therapeutics

Markus Müllner

CSO
Celeris Therapeutics
 

Jonathan Gast

Medicinal Chemistry, Application Scientist
Nanome

Jonathan Gast

Medicinal Chemistry, Application Scientist
Nanome

Jonathan Gast

Medicinal Chemistry, Application Scientist
Nanome
 

Racha Majed

Technical Sales Specialist
Refeyn

Racha Majed

Technical Sales Specialist
Refeyn

Racha Majed

Technical Sales Specialist
Refeyn
 

Michael Plewe

SVP, Medicinal Chemistry
Cullgen

Michael Plewe

SVP, Medicinal Chemistry
Cullgen

Michael Plewe

SVP, Medicinal Chemistry
Cullgen
 

Andreas Hofmann

Senior Principal Scientist
Novartis

Andreas Hofmann

Senior Principal Scientist
Novartis

Andreas Hofmann

Senior Principal Scientist
Novartis

The Agenda

The Protein Degradation & Targetting Undruggables 2022 Europe agenda is here!

Simply fill out the short form and access your copy immediately. 

DOWNLOAD THE 2022 AGENDA

Poster Session

Looking to showcase your recent work to the protein degradation community?

Our dedicated poster session is the perfect way to get your research noticed. Ideal for PhD students or Post-Doctoral researchers.

In order to present a poster at the forum you need to be registered as a delegate. Please note that there is limited space available and poster space is assigned on a first come first served basis (subject to checks and successful registration). At the congress, your presentation will be displayed in a dedicated poster area. 

Applications are now closed.

Abstracts received after this time may not be accepted so please submit your abstract as soon as possible!

Kisaco Research will provide boards and fixings. Delegates are responsible for bringing the copy of their poster to be presented. Posters should be sized A0 (841mm x 1189mm) in portrait orientation.

What attendees say

2022 Partners

Gold Partner

Event Partners

Become a partner

Kisaco Research provides the platform where industry executives can network, learn and meet potential industry partners.

Far from the typical ‘meet-and-greet’ experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand.

Your partnership with Kisaco Research will offer you a strategic approach that is an extension and enhancement of your own marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets.

Find out more by calling us at +44 (0)20 3696 2920 or email Ryan Sanderson at [email protected] 

Conference Packages

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

We accept the following cards through Stripe:

Registration ends in

Saturday, September 17, 2022 to Thursday, October 13, 2022
Tier 1 Academics
€1,899
Standard Pricing
Must be a full time academic
2 day conference pass
Networking opportunities
To increase your brand presence, contact [email protected]
Saturday, September 17, 2022 to Thursday, October 13, 2022
Tier 2 Drug developers
€2,699
Standard Pricing
Must have active degrader therapeutic pipeline and less than 10 years old
2 day conference pass
Networking opportunities
To increase your brand presence, contact [email protected]
Saturday, September 17, 2022 to Thursday, October 13, 2022
Tier 3 Industry
€3,599
Standard Pricing
2 day conference pass
Networking opportunities
To increase your brand presence, contact [email protected]
Preparing registration...

Venue

Congress Center Basel

Congress Center Basel, MCH Messe Schweiz (Basel) A, CH-4005 Basel

To view local hotels near to the event venue please click here.

Resources

Download Resource

highlights from previous years

Protein degradation Congress

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.

Contact Us